JB there are differences and similarities between Codiak and EX1 . EX1 is currently in the process of securing deals in relation to its technology as per Ian Dixon's update of 22/12. Whether Codiak is overvalued or not the MC's are totally out of whack , EX1 has a pipeline of news and developments ahead which will see it cement the expectations in my view. Blue Sky is what you buy when it is Blue Sky. The only pure exosome play on the ASX with one other in the world.
I think I have the answers to the more technical issues you raise but I'll seek the correct advice first.
As for ramping I've been telling people to get into this stock since before it listed because once exosomes became a thing it has superior management ,a stellar team , and a plan to commercialise research and production. I really believe this company has a huge future as does the uptake and development of exosomes as a regenerative medicine.
EX1 Price at posting:
57.0¢ Sentiment: Buy Disclosure: Held
